Fate Therapeutics presents Phase 1 data for off-the-shelf CAR-T FT819 in systemic lupus erythematosus at CCR-West 2026 - FATE News | RalliesFate Therapeutics presents Phase 1 data for off-the-shelf CAR-T FT819 in systemic lupus erythematosus at CCR-West 2026
F
FATE• Phase 1 FT819 data to be presented at CCR-West
- Fate Therapeutics set an encore clinical data presentation on FT819 at the CCR-West meeting on Sept. 18, 2026.
- Results were previously generated in an ongoing Phase 1 trial in systemic lupus erythematosus, with a May 14, 2026 data cutoff.
- Data showed a favorable safety profile in the treated group, supporting use with reduced conditioning and potential same-day discharge.
- Clinical activity was observed early, then maintained, reinforcing the rationale for the RECLAIM-LN Phase 2 trial in lupus nephritis.
- Fate also scheduled a preclinical FT839 presentation at the same session, positioning a dual-target CAR T approach for autoimmune disease.
•
